Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: A retrospective analysis of the German cohort of TEAM

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2566-2572

  Hadji, P ^a   Kieback, D G ^b   Tams, J ^c   Hasenburg, A ^d   Ziller, M ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b Elblandkliniken ^*  (Germany)

^c ICRC Weyer GmbH   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adverse events; Arthralgia; Exemestane; Myalgia; Postmenopausal; Tamoxifen

Indexed keywords

EXEMESTANE; TAMOXIFEN;

ADULT; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EARLY CANCER; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MYALGIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GERMANY; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 84867130491     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds055     Document Type: Article

References (28)

1. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20(8): 1319-1329.
2. Chlebowski R, Cuzick J, Amakye D et al. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 2009; 18 (Suppl 2): S1-S11.
3. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369(9561): 559-570.
4. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9(1): 45-53.
5. Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361 (8): 766-776.
6. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007; 18 (Suppl 8): viii26-viii35.
7. Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 2008; 1573-90.
8. Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 2005; 23(8): 1644-1655.
9. Miller WR, Bartlett J, Brodie AM et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist 2008; 13(8): 829-837.
10. Coleman RE, Bolten WW, Lansdown M et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008; 34(3): 275-282.
11. Hadji P, Ziller M, Kieback DG et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised sub-study. Ann Oncol 2009; 20(7): 203-207.
12. Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19(8): 1407-1416.
13. Amir E, Ocana A, Niraula S et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients Oral presentation at San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX 2010
14. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?. Oncology (Williston Park) 2003; 17(11) (Suppl 12): 23-28.
15. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006; 8 (Suppl 1): S7-S14.
16. Mortimer JE, Flatt SW, Parker BA et al. Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 2008; 108(3): 421-426.
17. van de Velde CJH, Rea D, Seynaeve C et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011; 377 (9762): 321-331.
18. Nelson M, Hercbergs A, Rybicki L et al. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132(10): 1041-1046.
19. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103(9): 763-773.
20. Cuzick J, Sestak I, Cella D et al. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008; 9(12): 1143-1148.
21. Bonanni B, Macis D, Maisonneuve P et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006; 24(22): 3708-3709.
22. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101(1): 113-121.
23. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23(36): 9312-9318.
24. Stearns V, Chapman J-A, Ma C et al. Treatment-emergent symptoms and the risk of breast cancer recurrence in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial Oral presentation at San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX 2009
25. Partridge AH, LaFountain A, Mayer E et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26(4): 556-562.
26. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006; 71(1-2): 1-9.
27. Ziller V, Kalder M, Albert US et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009; 20(3): 431-436.
28. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010; 73(2): 156-166.